Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation

Fig. 1

5-Azacytidine pretreatment resensitizes cisplatin-resistant DLBCL cell lines to cisplatin to varying degrees. A Plasma levels of cisplatin in human patients following intravenous injection of an 80 mg/m2 dose. Red points represent the determined value for the patient at that time point reported by a widely cited paper. Black points represent the mPBPK model-predicted value using typical physiological and biochemical parameters. The dashed line indicates the top clinically achievable dose. B The IC50 value was calculated using a cell viability assay. The dashed line indicates the top clinically achievable dose. C Bar chat of IC50 values for cisplatin in six DLBCL cell lines; *p < 0.05, **p < 0.01 and ***p < 0.001 (two-way ANOVA). D Bar chat of log2-transformed IC50 fold change values. E–J. Subcutaneous tumor growth, xenograft tumor images and tumor weights of xenografts from OCI-LY1 and SU-DHL2 tumor-bearing athymic nude mice. E and H *p < 0.05, **p < 0.01 and ***p < 0.001 (two-way ANOVA). G and I *p < 0.05, **p < 0.01 and ***p < 0.001 (t test). AZA: 5-azacytidine

Back to article page